Sonoma Pharmaceuticals (NASDAQ:SNOA) Announces Quarterly Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) posted its quarterly earnings results on Tuesday. The company reported ($0.33) earnings per share (EPS) for the quarter, FiscalAI reports. Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The company had revenue of $5.56 million for the quarter.

Sonoma Pharmaceuticals Trading Down 0.9%

Shares of SNOA stock traded down $0.01 during trading hours on Tuesday, reaching $1.10. The company’s stock had a trading volume of 122,376 shares, compared to its average volume of 117,490. The stock has a market capitalization of $5.26 million, a P/E ratio of -0.54 and a beta of 1.29. The firm’s fifty day simple moving average is $1.46 and its 200 day simple moving average is $2.52. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $6.92.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned approximately 3.59% of Sonoma Pharmaceuticals worth $222,000 as of its most recent filing with the Securities & Exchange Commission. 1.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.